Patents by Inventor Thomas Tuschl

Thomas Tuschl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11414422
    Abstract: 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: August 16, 2022
    Assignee: The Rockefeller University
    Inventors: Lodoe Lama, Thomas Tuschl, Daisuke Tomita, Dinshaw Patel, J. Fraser Glickman, Taku Kamei, Michael Miller, Yasutomi Asano, Rei Okamoto, Shogo Hashizume, Jumpei Aida, Toshihiro Imaeda, Mayako Michino, Takanobu Kuroita
  • Publication number: 20220185812
    Abstract: Tri-cyclyl nitrogen-containing heterocyclic compounds are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
    Type: Application
    Filed: March 12, 2020
    Publication date: June 16, 2022
    Applicants: The Rockefeller University, Memorial Sloan-Kettering Cancer Center
    Inventors: Daisuke TOMITA, Lodoe LAMA, Thomas TUSCHL, Dinshaw PATEL, J. Fraser GLICKMAN, Taku KAMEI, Michael MILLER, Yasutomi ASANO, Rei OKAMOTO, Shogo HASHIZUME, Jumpei AIDA, Toshihiro IMAEDA, Mayako MICHINO, Takanobu KUROITA
  • Publication number: 20210155625
    Abstract: 1-(3,4-Dihydro-1H-pyrido[4, 3-b]indol-2(5H)-yl)-2-hydroxyethanones are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
    Type: Application
    Filed: February 5, 2019
    Publication date: May 27, 2021
    Applicants: The Rockefeller University, Memorial Sloan-Kettering Cancer Center
    Inventors: Lodoe LAMA, Thomas TUSCHL, Daisuke TOMITA, Dinshaw PATEL, J. Fraser GLICKMAN, Taku KAMEI, Michael MILLER, Yasutomi ASANO, Rei OKAMOTO, Shogo HASHIZUME, Jumpei AIDA, Toshihiro IMAEDA, Mayako MICHINO, Takanobu KUROITA
  • Patent number: 11014956
    Abstract: The present disclosure provides, among other things, compounds comprising cyclic dinucleotides containing a 2',5' linkage useful in the design of research tools, as research tools, and as therapeutic modalities such as enzyme modulators.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: May 25, 2021
    Assignees: Memorial Sloan Kettering Cancer Center; The Rockefeller, University; Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Publication number: 20200299693
    Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
    Type: Application
    Filed: February 28, 2020
    Publication date: September 24, 2020
    Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
  • Publication number: 20200270602
    Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA, Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.
    Type: Application
    Filed: September 24, 2019
    Publication date: August 27, 2020
    Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
  • Patent number: 10633656
    Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: April 28, 2020
    Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Whitehead Institute for Biomedical Research, UNIVERSITY OF MASSACHUSETTS
    Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
  • Patent number: 10472625
    Abstract: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long dsRNA. Thus, these 21-23 nt fragments are the sequence-specific mediators of RNA degradation. A molecular signal, which may be their specific length, must be present in these 21-23 nt fragments to recruit cellular factors involved in RNAi. This present invention encompasses these 21-23 nt fragments and their use for specifically inactivating gene function. The use of these fragments (or chemically synthesized oligonucleotides of the same or similar nature) enables the targeting of specific mRNAs for degradation in mammalian cells, where the use of long dsRNAs to elicit RNAi is usually not practical, presumably because of the deleterious effects of the interferon response.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: November 12, 2019
    Assignees: Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V., Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research, University of Massachusetts
    Inventors: Thomas Tuschl, Phillip D. Zamore, Phillip A. Sharp, David P. Bartel
  • Publication number: 20190330257
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 31, 2019
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, JR., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 10385091
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: August 20, 2019
    Assignees: Memorial Sloan Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 10176292
    Abstract: The present invention provides STING crystals. The present invention also provides STING modulators that interact with sites present in and/or defined by such crystals. The present invention also provides methods of making and using such crystals and modulators. Other aspects and/or features of the present invention will be apparent to those skilled in the art, reading the present specification.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: January 8, 2019
    Assignees: Memorial Sloan-Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Roger Jones, Gunther Hartmann, Winfried Barchet, Thomas Zillinger, Weiyi Wang, Pu Gao, Liang Deng, Manuel Ascano, Jr.
  • Patent number: 10131686
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 20, 2018
    Assignees: Memorial Sloan Kettering Cancer Center, The Rockefeller University, Rutgers, The State University of New Jersey, University of Bonn
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 10023865
    Abstract: The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: July 17, 2018
    Assignee: Max-Planck-Gesellschaft zur Förderung de Wissenschaften e.V.
    Inventors: Thomas Tuschl, Javier Martinez, Agnieszka Patkaniowska, Henning Urlaub, Reinhard Luehrmann
  • Publication number: 20180127454
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Application
    Filed: December 8, 2017
    Publication date: May 10, 2018
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Publication number: 20180118777
    Abstract: The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS.
    Type: Application
    Filed: September 28, 2017
    Publication date: May 3, 2018
    Inventors: Dinshaw J. Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Patent number: 9840533
    Abstract: The present disclosure provides, among other things, novel cyclic-GMP-AMP (cGAMP) analogs, mimics, mimetics and variants, and compositions and kits thereof; methods of using the compounds as described herein for treating cancer, and immune disease, disorders, or conditions; methods of using the compounds as described herein for modulating cGAS and STING; and methods of designing or characterizing a cGAS modulator.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: December 12, 2017
    Assignees: Memorial Sloan Kettering Cancer Center, Rutgers, The State University of New Jersey, The Rockefeller University, University of Bonn
    Inventors: Dinshaw Patel, Thomas Tuschl, Manuel Ascano, Jr., Yang Wu, Yizhou Liu, Winfried Barchet, Gunther Hartmann, Thomas Zillinger, Roger Jones, Barbara L. Gaffney, Pu Gao
  • Publication number: 20170327822
    Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
    Type: Application
    Filed: December 22, 2016
    Publication date: November 16, 2017
    Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
  • Publication number: 20170067050
    Abstract: The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation.
    Type: Application
    Filed: September 7, 2016
    Publication date: March 9, 2017
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Thomas TUSCHL, Javier MARTINEZ, Agnieszka PATKANIOWSKA, Henning URLAUB, Reinhard LUEHRMANN
  • Patent number: 9567582
    Abstract: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3? ends mediate efficient target RNA cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target RNA can be cleaved by the produced siRNP complex.
    Type: Grant
    Filed: September 3, 2014
    Date of Patent: February 14, 2017
    Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, WHITEHEAD INSTITUTE OF BIOMEDICAL TECHNOLOGY, UNIVERSITY OF MASSACHUSETTS
    Inventors: Thomas Tuschl, Sayda Mahgoub Elbashir, Winfried Lendeckel
  • Patent number: 9550993
    Abstract: In Caenorhabditis elegans, lin-4 and let-7 enclode 22- and 21-nucleotide RNAs, respectively, that function as key regulators of developmental timing. Because the appearance of these short RNAs is regulated during development, they are also referred to as “small temporal RNAs” (stRNAs). We show that many more 21- and 22-nt expressed RNAs, termed microRNAs, (miRNAs), exist in invertebrates and vertebrates, and that some of these novel RNAs, similar to let-7 stRAN, are also highly conserved. This suggests that sequence-specific post-transcriptional regulatory mechanisms mediated by small RNAs are more general than previously appreciated.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: January 24, 2017
    Assignee: Max-Planck Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Thomas Tuschl, Mariana Lagos-Quintana, Winfried Lendeckel, Jutta Dammann, Reinhard Rauhut